Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Deerfield Management Reports New Stake in KaloBios Pharmaceuticals Inc (KBIO)

James E. Flynn‘s Deerfield Management has reported adding KaloBios Pharmaceuticals Inc (NASDAQ:KBIO) to its equity portfolio. Deerfield currently holds around 3.18 million shares of the company, the passive stake amassing 9.64% of the common stock.

KaloBios Pharmaceuticals

KaloBios Pharmaceuticals Inc (NASDAQ:KBIO) is a U.S.-based bio-therapeutic company, which is engaged in development of protein therapeutics. About a week ago, the company reported that its Phase 2 study of a monoclonal antibody for patients with severe asthma. The study was well tolerated but it didn’t meet its clinical endpoints. Amid the news, the stock of the company dropped by over 18% in the past several days, and overall, it lost almost 40% since the beginning of the year.

The analysts consider KaloBios Pharmaceuticals Inc (NASDAQ:KBIO)’s stock being “overweight” and set a target price of $9.00 per share, well above the current price of the stock. At the same time, the company has missed the estimates for its net income for the last several quarters.

Despite the poor performance of the company, investors seem to be bullish on KaloBios Pharmaceuticals Inc (NASDAQ:KBIO). In the previous round of 13F filings, several funds disclosed holding shares of KaloBios with many initiating their positions during the third quarter of 2013. Jean-Marie Eveillard‘s First Eagle Investment Management reported ownership of 875,000 shares, followed by Clough Capital Partners, led by Charles Clough, and Charles Davidson‘s Wexford Capital, with 400,000 and 278,500 shares respectively.

Deerfield reported the new stake added to its equity portfolio only a day after disclosing holding shares of Auspex Pharmaceuticals Inc (NASDAQ:ASPX), and Dicerna Pharmaceuticals Inc (NASDAQ:DRNA). Both companies went public recently and Deerfield reported holding significant amounts of shares in both of them.

Disclosure: none

Recommended Reading:

Hedge Fund Highlights: Warren Buffett, Bill Ackman & Richard Gerson

Becker Drapkin Ups Stake in Nano-Cap Special Diversified Opportunities Inc (SDOI)

Iroquois Capital Management Sends Letter to MGT Capital Investments Inc. (MGT) Board

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!